Louisiana Autism Patients Get Zelira Medical Marijuana Tinctures

Autism is a developmental disorder characterized by communication and behavioral difficulties from minor to extremely severe. There is no medical cure for autism and much remains mysterious about the condition. There is no blood test or similarly straightforward means of diagnosis, and can often be missed for years or even a lifetime by a physician.  Autism can express differently in every individual, with a broad range of symptoms and gradients of severity that can make treating symptoms even more challenging than gaining a diagnosis. Conventional treatments for symptoms of ASD, which include a variety of drugs to relieve seizures or behavioral and anxiety issues, often come with serious side effects of their own. While interventions like cognitive behavioral therapy and speech-language therapy can have a positive impact on outcomes for those with ASD, those with more severe conditions may require some form of medication. Yet again, the adverse side effects that come with these medications create an untenable Catch-22 for ASD patients and caregivers alike. Enter HOPE.

HOPE tinctures are the creation of Zelira Therapeutics and Erica Daniels, founder of Hope Grows for Autism, a nonprofit aimed at improving the lives of families affected by autism through research, education, and advocacy of natural treatments. Daniels is a proud partner of Zelira Therapeutics, which formed through a merger of Zelda and Ilera Therapeutics in 2019. As the mother of a child with severe autism, Daniels responded to years of traveling the country in an exhaustive but fruitless search for treatments for her son by forging her own path, using diet and medical cannabis to ensure a high quality of life for her son and family.

Through partnerships within the state of Louisiana, HOPE tinctures (which are specifically formulated with Autism Spectrum Disorder in mind) will be available exclusively through state-licensed medical marijuana dispensaries in the state to all patients and families bearing a doctor’s prescription. The tinctures will be available in two formulations, “HOPE1”, which is a 1:1 THC: CBD tincture, and “HOPE2”, a 5:1 THC: CBD tincture. 

Louisiana ranks higher than the national average for the percentage of autism diagnoses per capita and recently passed legislation in the state allows all Louisiana patients and families to receive medical cannabis through a doctor’s prescription for any condition. This makes it a perfect staging ground for this new partnership between the HOPE line of medical cannabis tinctures, Lousiana’s Ilera Holistic Healthcare, and Southern University’s Agricultural Center, through which the tinctures are grown, cultivated, processed, and packaged. With the introduction of the specially formulated and research-based HOPE tinctures into medical marijuana dispensaries across Louisiana, Erica Daniels is excited to bring the benefits of cannabis to other constituents in the ASD community.

HOPE™ was formulated by Zelira Therapeutics a leading global therapeutic medical cannabis company with access to the world’s largest and fastest growing cannabis markets. The company’s focus is on developing branded cannabis products for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain.

 

Julie Aitcheson

Julie Aitcheson

Julie Aitcheson is a freelance writer who has had articles published in Echo Quarterly, Communities Magazine (formerly Talking Leaves Magazine), Isabella, and All Things Girl. She received a full fellowship to the 2013 Stowe StoryLabs and won second place in the 2014 San Miguel Writers’ Conference nonfiction writing competition. She has published two young adult novels and is currently at work on her next book.


One comment

  • Avatar
    Luka

    October 16, 2020 at 4:37 am

    That’s great. We, at Hempika also cooperate with national autism association and people are super satisfied with results. Although we don’t have medical cannabis dispensaries like in the US, the future is promising. Children already get prescribed our CBD products for epilepsy and we hope that other conditions like autism will soon follow, but it will be a rough path to achieve this. The US has way better regulations/laws regarding cannabis and the whole world should take you as an example.

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 20 mins

In case you missed it. Weed Talk News 10/16/2020 via @ProCannaMedia

@GreenMarketRpt – 3 days

Green Market Report’s Marijuana Money October 16, 2020

@GreenMarketRpt – 5 days

Green Market Report Wins Big During 2020 Awards Season

Back to Top

You have Successfully Subscribed!